Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2020-01-06 Major Shareholding Noti…
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership by Invesco Ltd. in Mereo BioPharma Group plc, crossing a reporting threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2020-01-06 English
Second Price Monitoring Extn
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Second Price Monitoring Extension' for a specific security. It does not contain financial statements, management reports, or governance disclosures, but rather serves as a technical market announcement regarding trading parameters. As it is a standard regulatory market notice that does not fit into specific categories like M&A, dividends, or share buybacks, it falls under the RNS (Regulatory Filings) category.
2020-01-02 English
Price Monitoring Extension
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for a specific security. It does not contain financial statements, management reports, or corporate governance disclosures. As it is a standard regulatory notification regarding trading parameters that does not fit into specific categories like M&A, dividends, or share issues, it falls under the RNS (Regulatory Filings) category.
2020-01-02 English
Price Monitoring Extension
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for a specific security. It does not contain financial statements, management reports, or corporate governance disclosures. As it is a standard regulatory notification regarding trading mechanics that does not fit into specific categories like M&A, dividends, or share buybacks, it is classified as a general Regulatory Filing (RNS).
2019-12-31 English
Second Price Monitoring Extn
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Second Price Monitoring Extension' for Mereo BioPharma Group plc. It is a standard automated market announcement regarding trading volatility and auction extensions, which does not fit into specific categories like financial reports, M&A, or director dealings. Therefore, it falls under the fallback category for general regulatory announcements.
2019-12-27 English
Price Monitoring Extension
Regulatory Filings Classification · 100% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for a specific security. It does not contain financial statements, management reports, or corporate governance disclosures. As it is a standard regulatory market notice that does not fit into specific categories like M&A, dividends, or share buybacks, it falls under the fallback category for regulatory announcements.
2019-12-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.